Showing 5291-5300 of 5771 results for "".
- Neurotech Pharmaceuticals Granted Fast Track Designation from the FDA for the Treatment of Macular Telangiectasia Type 2https://modernod.com/news/neurotech-pharmaceuticals-granted-fast-track-designation-from-the-fda-for-the-treatment-of-macular-telangiectasia-type-2/2476300/Neurotech Pharmaceuticals announced that the FDA has granted Fast Track designation for the company’s development candidate, NT-501 or Renexus, for the treatment of macular telangiectasia type 2 (MacTel). Fast track is a designation by the FDA to facilitate the development and expedite the
- Pr3vent Completes Series A Financing Led By InFocus Capital Partnershttps://modernod.com/news/pr3vent-completes-series-a-financing-led-by-infocus-capital-partners/2476301/Pr3vent, a healthcare AI company developing machine vision for detecting eye disease in newborns, has closed a Series A financing led by InFocus Capital Partners. The announcement comes on the heels of a successful seed round in October 2018 led by the joint investment of Skyview Ventures and Tro
- ARISE-3 Phase 3 Clinical Trial of the RGN-259 for the Treatment of Dry Eye Syndrome is Initiated by ReGenTreehttps://modernod.com/news/arise-3-phase-3-clinical-trial-of-the-rgn-259-for-the-treatment-of-dry-eye-syndrome-is-initiated-by-regentree/2476304/ReGenTree, a joint venture between GtreeBNT and RegeneRx Biopharmaceuticals, announced that it has executed an agreement with Ora for the initiation of ARISE-3 to study the company’s new drug RGN-259 for the treatment of dry eye syndrome. ARISE-3 is a randomized, double masked, placebo cont
- One-Year Results from Phase 3 Eylea Trial in Diabetic Retinopathy Presentedhttps://modernod.com/news/one-year-results-from-positive-phase-3-eylea-trial-in-diabetic-retinopathy-presented-at-angiogenesis-symposium/2476306/Regeneron Pharmaceuticals announced that positive detailed 1-year results from the phase 3 PANORAMA trial evaluating Eylea (aflibercept) injection in patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR)
- Optical and Ophthalmology Cloud Solutions Provider KIDE Systems Becomes Topcon Healthcare Solutions EMEAhttps://modernod.com/news/optical-and-ophthalmology-cloud-solutions-provider-kide-systems-becomes-topcon-healthcare-solutions-emea/2476307/Following Topcon Healthcare Solutions’ acquisition of KIDE Systems in April 2018, KIDE Systems announced that it will take on the branding of its parent company Topcon Healthcare Solutions, part of Topcon Corporation. The brand change includes the change of KIDE System’s corporate name to Topcon
- Topcon Healthcare Solutions and Oculo Form Global Partnershiphttps://modernod.com/news/topcon-healthcare-solutions-and-oculo-form-global-partnership/2476308/Topcon Healthcare Solutions (THS) and Oculo, a technology provider in clinical communications based out of Melbourne, Australia, have announced a new partnership that will combine the strengths of their Topcon Harmony and Oculo eye care platforms. Financial terms of the deal were not disc
- Avedro Launches Initial Public Offeringhttps://modernod.com/news/avedro-launches-initial-public-offering/2476317/Avedro announced that it has commenced an initial public offering of 5 million shares of common stock. The initial public offering price is currently estimated to be between $14 and $16 per share. Avedro expects to grant the underwriters a 30-day option to purchase up to an additional 750,000 sha
- Graybug Vision Appoints Frédéric Guerard as Chief Executive Officerhttps://modernod.com/news/graybug-vision-appoints-frederic-guerard-as-chief-executive-officer/2476318/Graybug Vision announced that the board of directors has appointed Frédéric Guerard as Chief Executive Officer. Mr. Guerard’s career in the pharmaceutical industry spans over 20 years and includes multiple leadership, strategic, and commercial roles. He joins from Novartis, where he was pr
- GenSight’s Gene Therapy GS010 Fails Second Late-Stage Leber Hereditary Optic Neuropathy Studyhttps://modernod.com/news/gensights-gene-therapy-gs010-fails-second-late-stage-leber-hereditary-optic-neuropathy-study/2476321/GenSight Biologics announced that a phase 3 study investigating a single injection of the experimental gene therapy GS010 failed to improve vision loss compared to sham treatment in patients with 11778-ND4 Leber hereditary optic neuropathy (LHON). In the RESCUE study, patients with
- Bausch + Lomb Launches Sightmatters.com to Help People Living With AMDhttps://modernod.com/news/bausch-lomb-launches-sightmatters-com-to-help-people-living-with-amd/2476325/Bausch + Lomb announced the launch of SightMatters.com, a new educational online resource for people living with age-related macular degeneration (AMD). Bausch + Lomb launched the site to coincide with the start of AMD Awareness Month. The new online resource, which was specifically design